SOPH vs. IVVD, VTYX, AVXL, MGX, TCRX, GLUE, MGTX, TNYA, AURA, and CRBU
Should you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Invivyd (IVVD), Ventyx Biosciences (VTYX), Anavex Life Sciences (AVXL), Metagenomi (MGX), TScan Therapeutics (TCRX), Monte Rosa Therapeutics (GLUE), MeiraGTx (MGTX), Tenaya Therapeutics (TNYA), Aura Biosciences (AURA), and Caribou Biosciences (CRBU). These companies are all part of the "medical" sector.
SOPHiA GENETICS (NASDAQ:SOPH) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability.
31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 19.1% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Invivyd has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -126.63%. SOPHiA GENETICS's return on equity of -47.40% beat Invivyd's return on equity.
SOPHiA GENETICS received 10 more outperform votes than Invivyd when rated by MarketBeat users. Likewise, 72.73% of users gave SOPHiA GENETICS an outperform vote while only 60.00% of users gave Invivyd an outperform vote.
SOPHiA GENETICS presently has a consensus target price of $8.00, suggesting a potential upside of 58.10%. Invivyd has a consensus target price of $11.33, suggesting a potential upside of 399.27%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than SOPHiA GENETICS.
SOPHiA GENETICS has higher revenue and earnings than Invivyd. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
SOPHiA GENETICS has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
In the previous week, SOPHiA GENETICS had 5 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for SOPHiA GENETICS and 1 mentions for Invivyd. Invivyd's average media sentiment score of 0.00 beat SOPHiA GENETICS's score of -0.27 indicating that Invivyd is being referred to more favorably in the news media.
Summary
SOPHiA GENETICS beats Invivyd on 9 of the 16 factors compared between the two stocks.
Get SOPHiA GENETICS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SOPHiA GENETICS Competitors List
Related Companies and Tools
